Statistics

Total Visits

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial3

Select a period of time:

Number of views in the range

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial3

Views

Views
February 20263
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States2
Turkey1
 

Top cities views

Views
Council Bluffs1
Mersin1
Newton1